News2 mins ago
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update
─Reported Top-line Results from CM-101 Phase 2 Liver Fibrosis Trial in NASH Patients Demonstrating Safety and Positive Activity Across Multiple Fibrotic and Inflammatory Biomarkers─ ─Received FDA...
